Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed,
Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed, called BrachySeed Palladium-103. This is the second such offering by Cytogen and DraxImage. The first, BrachySeed I-125 containing radioactive iodine, was launched in 2001. The BrachySeed products complement Cytogen's ProstaScint, a monoclonal antibody-based agent used to image the extent and spread of prostate cancer.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.